E-mail: martina.divoka@hotmail.com
Odborné práce publikované na Linkos.cz
Přehled odborných textů publikovaných autorem na portálu Linkos.cz. Jsou zde uvedeny knihy a brožury, články v Klinické onkologii, tuzemská abstrakta z databáze abstrakt a další texty. Rejstřík není v žádném případě úplným autorským rejstříkem, protože jsou zde uvedeny pouze texty zveřejněné na portálu Linkos.cz.
Publikovaná abstrakta
- A CASE REPORT WITH E6A2 BCR-ABL FUSION TRANSCRIPT WITH MARKED BASOPHILIA AND HIGH ACTIVATION OF SRC KINASES DOWNSTREAM BCR-ABL
- Cytogenetic Aberration Profile of Chronic Myeloid Leukemia and Its Dynamic Changes During Imatinib Therapy
- EFFICACY OF IMATINIB DOSE ESCALATION (IDE) IN CHRONIC MYELOID LEUKEMIA (CML) PRETREATED WITH INTERFERON-? (INF-?)
- FCGRIIIA RECEPTOR GENOTYPE DOES NOT INFLUENCE AN OUTCOME IN PATIENTS WITH FOLLICULAR LYMPHOMA TREATED WITH RISK-ADAPTED IMMUNOCHEMOTHERAPY
- CHRONIC LYMPHOCYTIC LEUKAEMIA PATIENTS WITH V1-69 GENE REARRANGEMENT HAVE AN UNFAVOURABLE CLINICAL OUTCOME
- INTERFERON-ΑLPHA REVISITED: INDIVIDUALIZED IMMUNE-MODULATION EASED UP SELECTION PRESSURE OF TKI ON BCR-ABL MUTATED CLONES AND IMPROVES MOLECULAR RESPONSE IN HIGH-RISK CML PATIENTS
- INVESTIGATION OF 4 MOLECULAR MARKERS IN 65 PATIENTS WITH DE NOVO ACUTE MYELOID LEUKEMIA WITH NORMAL KARYOTYPE – A SINGLE CENTER EXPERIENCE
- LOWER DOSAGE OF IMATINIB (IM) IS SUFFICIENT TO MAINTAIN COMPLETE MOLECULAR RESPONSE (CMR) IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS WITH LONG-TERM TOXICITY OF THE TREATMENT
- MEASUREMENT OF TROUGH IMATINIB PLASMA LEVELS IN PATIENTS WITH CML DOES NOT SIGNIFICANTLY CORRELATE WITH TREATMENT RESPONSE BUT MAY BE SUCCESSFULLY USED IN SELECTED PATIENTS FOR DOSAGE ADJUSTMENT
- MOLECULAR CHARACTERIZATION OF BETA-THALASSEMIA AND HEMOGLOBIN VARIANTS IN THE CZECH AND SLOVAK POPULATIONS: AN UPDATE
- MUTATIONS IN IDH1/2 GENES IN ACUTE MYELOID LEUKEMIA WITH NORMAL KARYOTYPE: A SINGLE CENTRE STUDY OF 72 CASES
- OPERATIONAL CURE OF CHRONIC MYELOID LEUKEMIA AFTER TREATMENT WITH INTERFERON-ALPHA: A RETROSPECTIVE LONG-TERM STUDY FROM NORTHERN MORAVIA REGION
- SEQUENTIAL CHRONIC MYELOGENOUS LEUKEMIA (CML) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - 3 CASE REPORTS
- Stanovení a význam mutace V617F genu JAK2 u myeloproliferativních chorob
- Výskyt vybraných molekulárnych markerov v súbore 65 pacientov s de novo akútnou myeloidnou leukémiou a normálnym karyotypom - naše skúsenosti
